

Title	A degenerate PCR-based strategy as a means of identifying homologues of aminoglycoside and β -lactam resistance genes in the gut microbiota
Authors	Fouhy, Fiona; Ross, R. Paul; Fitzgerald, Gerald F.; Stanton, Catherine; Cotter, Paul D.
Publication date	2014-02-05
Original Citation	FOUHY, F., ROSS, R. P., FITZGERALD, G. F., STANTON, C. & COTTER, P. D. 2014. A degenerate PCR-based strategy as a means of identifying homologues of aminoglycoside and β -lactam resistance genes in the gut microbiota. BMC Microbiology, 14:25, 1-10. http://dx.doi.org/10.1186/1471-2180-14-25
Type of publication	Article (peer-reviewed)
Link to publisher's version	10.1186/1471-2180-14-25
Rights	© Fouhy et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. - http://creativecommons.org/licenses/by/2.0
Download date	2024-06-20 09:09:11
Item downloaded from	https://hdl.handle.net/10468/2253



UCC

University College Cork, Ireland
Coláiste na hOllscoile Corcaigh

RESEARCH ARTICLE

Open Access

A degenerate PCR-based strategy as a means of identifying homologues of aminoglycoside and β -lactam resistance genes in the gut microbiota

Fiona Fouhy^{1,2}, R Paul Ross^{1,3}, Gerald F Fitzgerald^{2,3}, Catherine Stanton^{1,3} and Paul D Cotter^{1,3*}

Abstract

Background: The potential for the human gut microbiota to serve as a reservoir for antibiotic resistance genes has been the subject of recent discussion. However, this has yet to be investigated using a rapid PCR-based approach. In light of this, here we aim to determine if degenerate PCR primers can detect aminoglycoside and β -lactam resistance genes in the gut microbiota of healthy adults, without the need for an initial culture-based screen for resistant isolates. In doing so, we would determine if the gut microbiota of healthy adults, lacking recent antibiotic exposure, is a reservoir for resistance genes.

Results: The strategy employed resulted in the identification of numerous aminoglycoside (acetylation, adenylation and phosphorylation) and β -lactam (including *bla*_{OXA}, *bla*_{TEM}, *bla*_{SHV} and *bla*_{CTX-M}) resistance gene homologues. On the basis of homology, it would appear that these genes originated from different bacterial taxa, with members of the *Enterobacteriaceae* being a particularly rich source. The results demonstrate that, even in the absence of recent antibiotic exposure, the human gut microbiota is a considerable reservoir for antibiotic resistance genes.

Conclusions: This study has demonstrated that the gut can be a significant source of aminoglycoside and β -lactam resistance genes, even in the absence of recent antibiotic exposure. The results also demonstrate that PCR-based approaches can be successfully applied to detect antibiotic resistance genes in the human gut microbiota, without the need to isolate resistant strains. This approach could also be used to rapidly screen other complex environments for target genes.

Keywords: Antibiotic resistance, Aminoglycosides, β -lactam, Gut microbiota, PCR

Background

Almost as soon as the widespread therapeutic use of antibiotics occurred, bacteria displaying diverse and complex mechanisms of resistance became problematic [1,2]. As the human gut is one of the most densely populated microbial environments, it has been postulated that it can act as a considerable reservoir for antibiotic resistance genes [3]. Thus, gut microbes may disseminate antibiotic resistance genes to other commensals or to bacteria transiently colonising the gut [4]. Given that antibiotics are known to exert significant and sustained negative effects on the gut microbiota [5,6], possessing resistance genes can provide a significant selective advantage to a subpopulation

of microorganisms in individuals undergoing antibiotic treatment [7]. The aminoglycosides and β -lactams are two large families of antibiotics which are frequently employed in clinical settings. The aminoglycosides, which were first characterised in 1944, [8] function by binding to the 30S subunit of the prokaryotic ribosome resulting in disruption to protein synthesis. Resistance to aminoglycosides can be through reduced aminoglycoside uptake or enzymatic modification of the aminoglycoside through acetylation (AAC), adenylation (ANT) or phosphorylation (APH). β -lactam antibiotics include the penicillins and cephalosporins and inhibit bacteria through disruption of cell wall biosynthesis [9,10]. Resistance to β -lactams can be due to alterations to penicillin binding proteins or to the porins in the outer membrane (in Gram negative targets) or alternatively through the production of β -lactamases,

* Correspondence: paul.cotter@teagasc.ie

¹Teagasc Food Research Centre, Moorepark, Fermoy, Cork, Ireland

³Alimentary Pharmabiotic Centre, Cork, Ireland

Full list of author information is available at the end of the article

which hydrolyse the eponymous β -lactam ring rendering the antibiotic inactive [11,12].

The question of the evolutionary origin of antibiotic resistance genes has been the subject of much attention [9,13,14]. For quite some time it was thought that resistance evolved following exposure of bacteria to new antibiotics [15]. However, it is now apparent that repositories of antibiotic resistance genes exist such that, following the development and application of new antibiotics, bacteria possessing or acquiring such genes will gain a selective advantage and thus resistance will increase over time [16,17]. Previous studies have employed PCR to detect resistance genes in specific pathogens [18,19], though studies employing PCR to detect resistance genes in complex microbial environments have been limited. In one instance, a PCR-based approach was used to investigate the prevalence of gentamycin resistance genes in resistant isolates from sewage, faeces (from cattle and chickens), municipal and hospital sewage water and coastal water [20]. The utilisation of a PCR approach in that instance resulted in the identification of diverse genes encoding gentamycin modifying enzymes from across a broad host range, thus demonstrating the suitability of a PCR-based approach to investigate resistance genes present in complex environments. However, the study did not investigate antibiotic resistance genes in human gut microbiota and, to our knowledge, to date no such PCR-based studies exist. Given these findings and other indications that there exist large natural pools of antibiotic resistance genes within complex microbial populations, it is likely that the human gut also contains many such genes. However, until now, PCR-based strategies to detect antibiotic resistance genes in the gut microbiota have involved an initial culture-based screen for resistant isolates, followed by subsequent PCR-based approaches to identify the associated resistance genes. This does not take into consideration the fact that the vast majority of gut microbes are not easily cultured [21], and thus antibiotic resistance genes from such microorganisms would typically be overlooked.

Here we utilise degenerate PCR primers to investigate the presence of β -lactam resistance genes and each of the three categories of aminoglycoside modifying enzymes within human metagenomic DNA and in doing so demonstrate that the human gut microbiota is a reservoir for antibiotic resistance genes. Additionally, we establish that a PCR-based approach allows the rapid detection of such genes in the complex gut microbiota environment, without the need for an initial isolation of strains.

Methods

Recruitment of volunteers

Forty adults were recruited and each provided written, informed consent for participation in this study. Approval for this trial was received from the Clinical Research

Ethics Committee of the Cork Teaching Hospitals, Cork, Ireland. Volunteers were aged 28.8 ± 3.8 years, were free from gastrointestinal disorders and had not been treated with antibiotics in the 6 months prior to sample collection. Fresh faecal samples were collected and stored at -80°C until processed.

DNA extraction

Stool samples were weighed, homogenised and due to the total volume provided by each individual, samples had to be pooled to achieve the required volume for our metagenomic DNA extraction protocol. To facilitate this, an equal volume (250 mg) from each individual was taken and pooled to form one sample, from which metagenomic DNA was extracted. The DNA extraction procedure used was optimised for total bacterial genomic DNA extraction from stool samples. The stool sample was homogenized in PBS and centrifuged at $1000\text{ g} \times 5$ mins and the supernatant was removed and retained. This was repeated 3 times. The supernatant then underwent Nycodenz (Axis Shield, UK) density gradient centrifugation separation, to separate out the bacterial cells from faecal matter. Following enzymatic lysis of bacterial cells using lysozyme and mutanolysin (Sigma Aldrich, Dublin, Ireland) protein precipitation using Proteinase K and ammonium acetate (Sigma Aldrich) was completed. Bacterial DNA was then precipitated and washed using standard chloroform and ethanol procedures. DNA was eluted in TE buffer.

PCR-based detection of β -lactam resistance gene homologues

PCR-based detection of β -lactam resistance genes was completed using primers (MWG Eurofins, Germany) for the genes *bla*_{TEM} [22,23], *bla*_{SHV} [24] (both of which are classified as Bush group 2b β -lactamases), *bla*_{CTX-M} [25] (an extended spectrum β -lactamase (ESBL) which confers resistance to cefotaxime), *bla*_{OXA} [24] (ESBL, Bush group 2d ESBL) and *bla*_{ROB} [23] (confers high level ampicillin resistance) (Table 1). PCRs were completed using bacterial metagenomic DNA and all PCRs were performed in triplicate. PCRs were completed on a G-storm PCR machine and for the primer sets *bla*_{TEM} primer set 1 (RH605/606), *bla*_{TEM} primer set 2 and *bla*_{CTX-M}, PCRs were completed as previously outlined. For the primers *bla*_{OXA} and *bla*_{ROB} the PCR conditions were as follows: heated lid 110°C , $94^{\circ}\text{C} \times 5$ mins followed by 30 cycles of $94^{\circ}\text{C} \times 30\text{s}$, $64^{\circ}\text{C} \times 30\text{s}$ (*bla*_{OXA}) or 62°C (*bla*_{ROB}) and $72^{\circ}\text{C} \times 30\text{s}$ followed by $72^{\circ}\text{C} \times 10$ mins and held at 4°C . For *bla*_{SHV} PCRs were performed as follows: heated lid 110°C , $94^{\circ}\text{C} \times 5$ mins followed by 35 cycles of $94^{\circ}\text{C} \times 30\text{s}$, $58^{\circ}\text{C} \times 30\text{s}$ and $72^{\circ}\text{C} \times 30\text{s}$ followed by a final extension step of $72^{\circ}\text{C} \times 10$ mins and held at 4°C . All PCRs contained 25 μl Biomix Red (Bioline, UK), 1 μl forward primer (10pmol concentration), 1 μl reverse primer (10pmol concentration),

Table 1 Primers used for the detection of β -lactamase and aminoglycoside resistant genes

Location	Primer	Sequence 5'-3'	Amplicon Size (bp)	Annealing Temp°C	Source
β-lactamase genes					
<i>Bla</i> _{TEM}	RH605	TTTCGTGTCGCCCTTATTCC	692	60	Bailey <i>et al.</i> (2011) [22]
	RH606	CCGGCTCCAGATTATCAGC			
	Bla_TEMF	TGGGTGCACGAGTGGGTTAC	526	57	Tenover <i>et al.</i> (1994) [23]
	Bla_TEMR	TTATCCGCCTCCATCCAGTC			
<i>Bla</i> _{ROB}	Bla_ROBF	ATCAGCCACACAAGCCACCT	692	62	Tenover <i>et al.</i> (1994) [23]
	Bla_ROBR	GTTTGGGATTTGGTATGCGA			
<i>Bla</i> _{SHV}	Bla_SHVF	CACTCAAGGATGTATTGTG	885	58	Briñas <i>et al.</i> (2002) [24]
	Bla_SHVR	TTAGCGTTGCCAGTGCTCG			
<i>Bla</i> _{OXA}	Bla_OXAF	TTCAAGCCAAAGGCACGATAG	702	64	Briñas <i>et al.</i> (2002) [24]
	Bla_OXAR	TCCGAGTTGACTGCCGGGTTG			
<i>Bla</i> _{CTX-M}	Bla_CTX-MF	CGTTGTA AACGACGCGCCAGTGAATGTGCAGYACCAGTAARGTKATGGC	600	55	Monstein <i>et al.</i> (2009) [25]
	Bla_CTX-MR	TGGGTRAARTARGTSACCAGAAYCAGCGG			
AG resistant genes					
<i>aac</i> (3)-I	Faac3-1	TTCATCGCGCTTGCTGCVITYGA	239	58	Heuer <i>et al.</i> (2002) [20]
	Raac3-1	GCCACTGCGGGATCGTRCCRTA			
<i>aac</i> (3)-II/VI	Faac3-2	GCGCACCCCGATGCMTCSATGG	189	58	
	Raac3-2	GGCAACGGCCTCGGCGTARTGSA			
	Facc3-6	GCCCATCCCGACGCATCSATGG			
	Raac3-6	CGCCACCGCTTCGGCATARTGSA			
<i>aac</i> (6)-II/Ib	Faac6	CACAGTCGTACGTTGCKCTBGG	235	58	
	Raac6	CCTGCCTTCTCGTAGCAKCGDAT			
<i>ant</i> (2)-I	Fant	TGGGCGATCGATGCACGGCTRG	428	58	
	Rant	AAAGCGGCACGCAAGACCTCMAC			
<i>aph</i> (2 ^m)-I	Faphc	CCCAAGAGTCAACAAGGTGCAGA	527	55	
	Faphd	GGCAATGACTGTATTGCATATGA	572	55	
	Raph	GAATCTCCAAAATCRATWATKCC			
<i>aac</i> (6 ^m)-Ie- <i>aph</i> (2 ^m)-Ia	aac-aphF	GAGCAATAAGGGCATAACCAAAAATC	505	47	De Fatima Silva Lopes <i>et al.</i> (2003) [26]
	aac-aphR	CCGTGCATTTGTCTTAAAAAACTGG			
	aac6-aph2F	CCAAGAGCAATAAGGGCATAACC	222	55	Schmitz <i>et al.</i> (1999) [27]
	aac6-aph2R	CACACTATCATAACCATCACCG			

AG: aminoglycoside. Type of gene i.e. beta-lactamase or AG given in bold.

metagenomic DNA (64 ng) and PCR grade water (Bioline, UK), to a final volume of 50 μ l. Negative controls were completed for all primer sets. Gel electrophoresis was performed on all samples using 1.5% agarose gel in 1 \times TAE buffer.

PCR-based detection of aminoglycoside resistance gene homologues

For the detection of aminoglycoside resistant genes, degenerate primer sets were used which had previously been designed and shown to amplify all known genes encoding gentamycin-modifying enzymes and similar, but as yet undiscovered, sequences [20]. PCRs were completed using primer sets (MWG Eurofins, Germany) for genes belonging to each group of aminoglycoside modifying enzymes namely, acetylation, adenylation and phosphorylation enzymes. DNA from positive controls (kindly gifted to us from the Smalla laboratory, JKI, Braunschweig) namely *Escherichia coli* S17-1 pAB2002 (*aac* (3)-Ia), *Pseudomonas aeruginosa* 88.341 F (*aac* (3)-Ib), *Enterobacter aerogenes* 17798 VDK (*aac* (3)-IIa), *E. coli* DH5 α pSCH4203 (*aac* (3)-IIb), *E. coli* DH5 α pSCH4101 (*aac* (3)-VIa), *P. aeruginosa* PST-1 (*aac* (3)-IIIa), *Acinetobacter baumannii* LBL.3 (*aac* (6')-Ib), *P. aeruginosa* F-03 (*aac* (6')-IIa), *E. coli* DH5 α pSCH5102 (*aac* (6')-IIb), *E. coli* CV600 pIE723 (*ant* (2'')-I), *E. coli* DH5 α pAM6306 (*aph* (2'')-Ic) and *E. coli* NC95 (*aph* (2'')-Id) were used as positive controls for the PCR reactions. This ensured the specificity of the respective primer pairs. PCRs for the detection of acetylation genes *aac* (3)-I, *aac* (3)-II, *aac* (3)-III, *aac* (3)-VI and *aac* (6), adenylation genes *ant* (2'')-Ia and phosphorylation genes *aph* (2'')-Ic and *aph* (2'')-Id were completed as previously outlined [20] (Table 1). Additionally, PCRs using primers for the bifunctional gene *aac* (6'')-Ie-*aph* (2'') [26,27] (which encodes enzymes responsible for high level gentamycin resistance, as well as concomitant resistance to tobramycin and kanamycin) [27-31] were completed as follows: heated lid 110°C, 94°C \times 5 mins followed by 30 cycles of 94°C \times 30s, 47°C \times 30s, 72°C \times 30s, with a final extension step of 72°C \times 10 mins and held at 4°C. All PCRs contained 25 μ l Biomix Red (Bioline, UK), 1 μ l forward primer (10pmol concentration), 1 μ l reverse primer (10pmol concentration), metagenomic DNA (64 ng) and PCR grade water (Bioline, UK), to a final volume of 50 μ l. Negative controls were run for all primer sets. All PCRs were performed in triplicate and analysed using gel electrophoresis, as described above.

Cloning of PCR amplicons

Triplicate samples from successful PCR reactions were pooled and cleaned using AMPure magnetic bead-based PCR clean up kit (Beckman Coulter, UK). TOPO cloning reactions were performed on purified PCR products using the TOPO TA cloning kit (Invitrogen, Dublin, Ireland) to

facilitate the sequencing of individual gene fragments. TOPO cloning reactions were then cloned into TOP10 *E. coli* (Invitrogen) as per the manufacturer's instructions and plated onto LB (Difco) containing the appropriate antibiotic (either ampicillin 50 μ g/ml or kanamycin 50 μ g/ml; Sigma Aldrich, Dublin, Ireland) to select for the presence of the cloning vector. Transformants were selected from each TOPO cloning reaction and grown overnight in LB broth containing the suitable selective antibiotic (either ampicillin 50 μ g/ml or kanamycin 50 μ g/ml). Plasmids were extracted from overnight samples using QIAprep Spin Mini Prep kit (Qiagen, Sussex, UK) according to the manufacturer's instructions and sent for Sanger sequencing (Source BioSciences, Dublin, Ireland).

Bioinformatic analysis

Following Sanger sequencing, sequence reads were analysed using the NCBI protein database (BlastX; (<http://blast.ncbi.nlm.nih.gov/>)). In the event where multiple hits occurred, the BLAST hit which displayed greatest homology is reported.

Results and discussion

A PCR-based approach highlights the presence of β -lactamase gene homologues in the gut microbiota

The results of the β -lactamase-specific PCRs demonstrated the presence and diversity of class 2 β -lactamase genes in the gut microbiota of healthy adults (Table 2 [32]). Of the β -lactam primers used, the primers designed to amplify *bla*_{TEM} genes yielded the greatest number of unique sequence hits (42% of selected TOPO sub-clones gave a unique hit). The majority of these genes exhibited a high percentage identity with genes from various members of the *Proteobacteria* including *E. coli*, *Klebsiella*, *Salmonella*, *Serratia*, *Vibrio parahaemolyticus* and *Escherichia vulneris*. The resistance of strains of *Salmonella* and *Serratia* to β -lactams via *bla*_{TEM} genes has been noted [33-35] and such strains have been associated with nosocomial infections [36]. In contrast, there have been relatively few studies of *bla*_{TEM} genes in *Vibrio parahaemolyticus* and *Escherichia vulneris* [37,38]. The identification of genes homologous to those from *Enterobacteriaceae* is not surprising given the prevalence of resistance genes among members of this family [12]. It was notable that the *bla*_{TEM} primers also amplified genes that resembled *bla*_{TEM} genes from some more unusual sources, including two genes from uncultured bacteria and from a Sar 86 cluster (a divergent lineage of γ -*Proteobacteria*) bacteria. This approach can thus provide an insight into possible novel/unusual sources of resistance genes, including those that culture-based approaches would fail to detect. Such results also highlight that had initial screening for resistant isolates been completed prior to PCR amplification of the resistance genes, such unusual sources of resistance genes may have been

Table 2 Homologues of β -lactamase genes detected in the human gut microbiota via PCR techniques

Accession #	Gene description	Closest homologue	E value	% identity
Bla_{TEM}				
ADE18890.1	β -lactamase TEM-1	<i>S. enterica</i> subsp. <i>enterica</i>	5e ⁻¹⁵⁴	99
AAS46844.1	β -lactamase TEM-1	<i>S. marcescens</i>	2e ⁻¹⁵⁶	100
AEN02824.1	β -lactamase TEM-1	<i>K. pneumoniae</i>	3e ⁻¹¹¹	99
AEN02817.1	β -lactamase TEM-1	<i>K. pneumoniae</i>	1e ⁻¹¹³	99
ACV88636.1	β -lactamase TEM-1	<i>E. coli</i>	2e ⁻¹⁵¹	99
AEL87577.1	ES β -lactamase TEM-116	<i>Vibrio parahaemolyticus</i>	5e ⁻¹⁵⁴	99
AEQ55231.1	β -lactamase TEM-1	<i>E. coli</i>	1e ⁻³⁵	45
ABQ14376.1	β -lactamase	Uncultured soil bacterium	6e ⁻⁰⁵	83
ADN79104.1	β -lactamase TEM	<i>Escherichia vulneris</i>	1e ⁻¹⁵	86
WP_010157942.1	β -lactamase TEM	<i>Sar 86 cluster bacterium</i>	9e ⁻¹²²	83
ACI29961.1	β -lactamase TEM-1	<i>E. coli</i>	2e ⁻¹⁵³	99
AEQ39590.1	β -lactamase TEM-195	<i>E. coli</i>	5e ⁻⁹³	96
AAM22276.1	β -lactamase TEM-96	<i>E. coli</i>	7e ⁻¹³⁹	94
WP_019405145.1	β -lactamase TEM	<i>K. pneumoniae</i>	4e ⁻¹⁵⁵	99
AEW28787.1	β -lactamase TEM-1	Uncultured bacterium	1e ⁻¹³³	100
ABY81267.1	β -lactamase	<i>E. coli</i>	4e ⁻¹⁵⁶	100
AAF74292.1	ES β -lactamase	<i>E. coli</i>	5e ⁻¹⁵⁵	99
AFU53026.1	KPC-2 β lactamase	<i>S. marcescens</i>	2e ⁻¹¹²	98
ADE18896.1	β -lactamase TEM-1	<i>Salmonella enterica</i>	2e ⁻¹¹³	99
AEN02826.1	β -lactamase TEM-1	<i>K. pneumoniae</i>	4e ⁻¹¹³	99
Bla_{ROB}				
YP_252228.1	Hypothetical protein SH0313	<i>S. haemolyticus</i>	2e ⁻³³	44
Bla_{SHV}				
WP_009348253.1	Hypothetical protein HMPREF 9332	<i>Alloprevotella rava</i>	3e ⁻⁰⁷	56
WP_017896153.1	β -lactamase	<i>K. pneumoniae</i> subsp. <i>pneumoniae</i>	0.0	99
WP_008157744.1	Hypothetical protein HMPREF 1077	<i>Parabacteroides johnsonii</i>	1.5	29
CAJ47138.2	β -lactamase	<i>K. pneumoniae</i>	0.0	99
ADU15837.1	BlaSHV132	<i>K. pneumoniae</i>	0.0	99
AEK80394.1	β -lactamase SHV140	<i>K. pneumoniae</i>	0.0	99
ABS72351.1	β -lactamase SHV103	<i>K. pneumoniae</i>	0.0	99
AAP03063.1	β -lactamase SHV48	<i>K. pneumoniae</i>	0.0	99
AEG79634.1	ES β -lactamase SHV120	<i>E. coli</i>		99
Bla_{CTX-M}				
ABG46354.1	ES β -lactamase	<i>E. coli</i>	3e ⁻¹³⁹	99
AEZ49563.1	β -lactamase CTX-M-1	<i>E. coli</i>	2e ⁻¹³⁸	99
AEZ49551.1	β -lactamase CTX-M-1	<i>K. pneumoniae</i>	1e ⁻¹³⁹	100
ABG46356.1	ES β -lactamase	<i>K. pneumoniae</i>	9e ⁻¹³⁹	97
ABW06480.1	ES β lactamase CTX-M-15	<i>K. pneumoniae</i>	6e ⁻⁵¹	94
AAB22638.1	β -lactamase penicillin hydrolase	<i>E. coli</i>	9e ⁻¹⁴⁰	100
BAD16611.1	β -lactamase CTX-M-36	<i>E. coli</i>	8e ⁻¹³⁹	99
YP_003717483.1	β -lactamase	<i>E. coli</i>	2e ⁻¹³⁹	100
ABN09669.1	β -lactamase CTX-M-61	<i>S. enterica</i>	2e ⁻¹³⁸	100

ESBL: extended spectrum β -lactamase. Gene names are in bold.

overlooked. Additionally, genes encoding ESBLs, including *bla*_{TEM-116}, *bla*_{TEM-195} and *bla*_{TEM-96} amongst others, were also identified, with their closest homologues being members of the *Proteobacteria* (Table 2).

Using the *bla*_{SHV} primers, multiple genes sharing homology with genes from members of the *Enterobacteriaceae*, and *Klebsiella* and *E. coli* in particular were detected. In addition, amplicons with low percentage identity to genes from *Alloprevotella rava* and *Parabacteroides johnsonii*, respectively, were also identified. This is again consistent with existing research which states that *Enterobacteriaceae* are the primary source of *bla*_{SHV} genes [39-43]. Furthermore, the amplicons sequenced resembled various different types of ESBL-encoding SHV genes, including *bla*_{SHV-132}, *bla*_{SHV-140} and *bla*_{SHV-48}, thus again highlighting the genuine degeneracy of the primers used.

Additional PCRs were completed to identify other ESBLs, specifically CTX-M- and OXA-type β -lactamases (Table 2). A number of different CTX-M β -lactamases were detected, including CTX-M-1, CTX-M-15 and CTX-M-36. The fact that many of the β -lactamase genes detected using our approach share homology with resistance genes found in members of the phylum *Proteobacteria* is not surprising as, despite being typically less common than the *Bacteroidetes* or *Firmicutes* in the gut microbiota of healthy adults [21], members of this genus have been identified as sources of antibiotic resistance genes and have been frequently associated with nosocomial infections and outbreaks [36,39,44,45]. In the 1990s, TEM- and SHV-type ESBLs were the β -lactamases most frequently observed among *Enterobacteriaceae* [18]. However, more recently, CTX-M-type ESBLs have spread rapidly and are now the most prevalent ESBL in *Enterobacteriaceae* in several parts of the world [46]. In a recent report on antibiotic resistance threats in the USA, the Centre for Disease Control stated that ESBL-producing *Enterobacteriaceae* were a serious public health threat [47]. The report estimates that 26,000 infections and 1,700 deaths that occur each year in the United States are attributable to ESBLs and that upwards of 140,000 health-care related *Enterobacteriaceae* infections occur annually. Therefore the detection of homologues of ESBL-encoding genes in the gut microbiota of healthy individuals is significant and provides evidence of the ubiquitous nature of these resistance genes, even in the absence of recent antibiotic exposure. With respect to the CTX-M-type ESBLs, it is particularly notable that homologues of the *bla*_{CTX-M-15} gene were detected, as these have received significant attention due to their recent rapid spread and their association with multi-drug resistant *E. coli* responsible for outbreaks of antibiotic resistant infections [48,49]. In such cases, these genes have been found on multi-drug resistance-encoding regions of plasmids, thus facilitating the rapid transfer of these genes. The presence of such genes within the gut microbiota

raises concerns that horizontal gene transfer may occur between commensals or to bacteria passing through the gut. If the resistance genes detected in our study are, or were to become, mobile, it would enable the gut to act not only as a source of resistance genes, but also as a site of resistance gene transfer. Although outside the scope of this study, studies investigating whether these genes are located on or near mobile genetic elements would be pertinent to ascertain the risk of the gut acting as a site for horizontal gene transfer.

When the *bla*_{ROB} primer set was employed to detect the presence of homologues of these ampicillin resistance-encoding genes, all amplicons sequenced were identical and shared 44% identity to *Staphylococcus haemolyticus bla*_{ROB} gene. Finally, this study did not detect *bla*_{OXA} gene homologues in our metagenomic sample. These findings are unexpected and may have occurred as a result of the particular affinity of the primer sets used.

A PCR-based approach highlights the presence of aminoglycoside resistance encoding gene homologues in the gut microbiota

Degenerate primers were selected that amplify genes encoding aminoglycoside modifying enzymes from each of the enzyme modification groups, namely acetylation, adenylation and phosphorylation [32]. When primers were applied to detect acetylation-associated genes, it was established that the primers designed to target *aac* (3)-I, *aac* (3)-II, and *aac* (3)-III homologues did not generate amplicons. In each of these PCR reactions the positive controls successfully amplified, thus we are satisfied that the lack of amplification products for our metagenomic sample is a true result. However, a number of distinct *aac* (6) and *aac* (3)-VI homologues were detected and were found to resemble genes from a variety of genera, including *Acinetobacter*, *Pseudomonas* and *Enterobacter* (Table 3). The presence of aminoglycoside acetylation genes within these genera has been noted previously [50-53]. The detection of resistance genes resembling those seen in *A. baumannii* is a concern, as many strains of this species have been shown to exhibit multi-drug resistance [54,55]. In addition, homologues of genes from *Collinsella* and *Salmonella* were also detected. Primers designed to amplify bifunctional *aac* (6')-Ie-*aph* (2') genes were also employed. Our investigations revealed the presence of homologues of such genes, resembling those from *S. aureus*, *E. faecium* and *S. epidermidis*, all of which are known sources of these genes [27,56,57].

Homologues of aminoglycoside phosphorylation-encoding genes were also detected using a PCR-based approach, with both *aph* (2'')-Ic and *aph* (2'')-Id like genes being detected. These genes shared homology with genes from *Enterococcus* species, including *E. faecium* and *E. casseliflavus*. Aminoglycoside resistant *E. faecium* have received

Table 3 Homologues of aminoglycoside resistance genes detected in the human gut microbiota via PCR techniques

Accession #	Gene description	Closest homologue	E value	% identity
aac (6)				
AAA25680.1	AG 6'-N-acetyltransferase	<i>Pseudomonas fluorescens</i>	4 e ⁻⁴⁸	98
WP_006234103.1	Hypothetical protein Colaer00186	<i>Collinsella aerofaciens</i>	0.0	95
AAS45464.1	6'-N-acetyltransferase	<i>A. baumannii</i>	3e ⁻³³	75
aac (6')-Ie-aph (2'')				
WP_002304968.1	Phosphotransferase	<i>E. faecium</i>	9e ⁻¹⁰⁸	100
WP_001028140.1	Acetyltransferase GNAT	<i>S. aureus</i>	1e ⁻¹⁰⁷	99
WP_001028143.1	Acetyltransferase GNAT	<i>S. aureus</i>	1e ⁻¹⁰⁷	99
WP_010729367.1	Bifunctional AAC/APH partial sequence	<i>E. faecium</i>	5e ⁻¹⁰⁶	99
AAX82584.1	Bifunctional AG modifying enzyme	<i>Enterococcus faecalis</i>	2e ⁻¹¹²	100
WP_002417297.1	6' AG acetyltransferase	<i>E. faecalis</i>	3e ⁻¹¹¹	97
AFR11868.1	Bifunctional AG 6'-N acetyltransferase/2'-AG phosphotransferases	<i>S. epidermidis</i>	1e ⁻⁴³	99
AFM29914.1	Gentamycin resistance protein	<i>Enterococcus</i> sp.	7e ⁻⁴⁵	97
aph (2'') Id				
3SG8_A	Chain A crystal structure AG 2' phosphotransferases	<i>E. casseliflavus</i>	1e ⁻¹¹⁰	98
3N4T_A	Aph2'' chain a	<i>E. casseliflavus</i>	2e ⁻¹¹⁰	99
AAT77696.1	AG modifying enzyme	<i>E. faecium</i>	1e ⁻⁶⁸	94
Aph (2'')-Ic				
3TDVA	AG phosphotransferase	<i>Enterococcus gallinarum</i>	2e ⁻⁸³	97
ant (2'') Ia				
YP_005176240.1	AG 2'-O-adenyltransferase	<i>Pasteurella mutocida</i>	2e ⁻⁹⁷	100
WP_000314377.1	2' AG nucleotidyltransferase	<i>A. baumannii</i>	3e ⁻⁹⁴	99
WP_000946493.1	2' AG	<i>A. baumannii</i>	1e ⁻⁹⁴	99
ACJ47203.1	AG adenytransferase	<i>E. coli</i>	6e ⁻⁹⁴	99
ACA48663.14	AG adenytransferase	<i>Morganella morganii</i>	2e ⁻⁹⁶	99
aac(3)-VI				
AAA16194.1	aac 3-6	<i>Enterobacter cloacae</i>	2e ⁻⁰⁵	77
WP_001642188.1	AG acetyltransferase	<i>S. enterica</i> subsp <i>enterica</i>	2e ⁻²⁰	98

AG: aminoglycoside. Gene names are in bold.

significant attention due to their role in nosocomial infections [58,59]. Notably, the role of mobile genetic elements in the maintenance and dissemination of multi-drug resistance in *Enterococcus faecalis* and *E. faecium* has previously been highlighted [30,60,61]. While it is not certain that the genes identified in this study are also associated with mobile elements, the possibility that resistance genes could be transferred to commensals is a concern. Homologues of aminoglycoside adenylation genes, *ant* (2'')-Ia, were also successfully detected. These resembled genes from *Pasteurella*, *Acinetobacter* and *E. coli* (Table 3), and the findings are thus consistent with previous research showing that these genes are most frequently detected in Gram negative bacteria [62]. Overall, the results demonstrate that the gut microbiota is a source of diverse aminoglycoside and β -lactam resistance genes, despite

having had no recent antibiotic exposure. If these genes are expressed there is the potential that if antibiotic exposure occurred, bacteria containing these resistance genes would become the dominant component of the gut microbiota, as has been shown in previous studies [5,63].

Conclusions

This study has highlighted the merits of applying a PCR-based approach to detect antibiotic resistance genes within the human gut microbiome. The results clearly demonstrate that the human gut microbiota is a considerable reservoir for resistance genes. Further studies are required to determine the exact sources of these genes and to determine if they have the potential to become mobile. Additionally, we have highlighted the successful application of a PCR-based screen of a complex environment without

prior isolation of resistant isolates. The possibility exists to couple this approach with lower throughput next generation sequencing strategies, such as that provided by the Ion PGM 314 chip, in instances where great diversity is likely. Our approach could also be used in conjunction with functional screening of metagenomic libraries to enable the detection of genes present in a complex environment at a low threshold and that may have avoided capture in the metagenomic library, as shown in a recent study [64]. Such a PCR-based approach is not being proposed as a substitute for ultra-deep high-throughput shotgun sequencing of metagenomic DNA, rather it is a lower cost, more targeted, alternative which facilitates the detection and *in silico* analysis of specific gene sets of interest. Finally, while this study demonstrates that the gut microbiota is a source of diverse resistance genes, further studies are required to investigate the exact sources of these genes, their expression and whether they have the potential to become mobile. As the scientific community continues to gain knowledge with respect to the genetic mechanisms involved in providing resistance to various antibiotics, the design of additional sets of degenerate primers will be possible and will provide further opportunities for the use of PCR to rapidly and efficiently detect antibiotic resistance genes in complex microbial environments, including the human gut microbiota.

Availability of supporting data

The data sets supporting results of this article are available in the LabArchives repository, [http://dx.doi.org/10.6070/H42V2D1V].

Abbreviations

AAC: Acetylation enzymes; APH: Phosphorylation enzymes; ANT: Adenylation enzymes; ESBL: Extended spectrum β -lactamase; AG: Aminoglycoside.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

FF conceived the study, was involved in the study design, performed the laboratory experiments and analysis and wrote the manuscript. RPR was involved in the study design and the drafting of the manuscript. GFF was involved in drafting of the manuscript. CS was involved in the study design and drafting of the manuscript. PDC conceived the study, was involved in the study design, interpretation of the data and drafting of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors wish to acknowledge the advice, assistance and protocols received from Dr. Brian Jones and Dr. Lesley Ogilvie regarding metagenomic sample preparation and analysis. Additionally the authors acknowledge the gift of control bacteria strains from the Smalla laboratory, JKI, Braunschweig. Fiona Fouhy is in receipt of an Irish Research Council EMBARK scholarship and is a Teagasc Walsh fellow. Research in the PDC laboratory is also supported by the Irish Government under the National Development Plan through the Science Foundation Ireland Investigator award 11/PI/1137.

Author details

¹Teagasc Food Research Centre, Moorepark, Fermoy, Cork, Ireland. ²School of Microbiology, University College Cork, Cork, Ireland. ³Alimentary Pharmabiotic Centre, Cork, Ireland.

Received: 12 August 2013 Accepted: 3 February 2014

Published: 5 February 2014

References

1. Davies J, Davies D: Origins and evolution of antibiotic resistance. *Microbiol Mol Biol Rev* 2010, **74**:417–433.
2. Abraham E, Chain E: An enzyme from bacteria able to destroy penicillin. *Nature* 1940, **146**:837–837.
3. Salyers AA, Gupta A, Wang Y: Human intestinal bacteria as reservoirs for antibiotic resistance genes. *Trends Microbiol* 2004, **12**:412–416.
4. Broaders E, Gahan CG, Marchesi JR: Mobile genetic elements of the human gastrointestinal tract: potential for spread of antibiotic resistance genes. *Gut microbes* 2013, **4**:271–280.
5. Dethlefsen L, Huse S, Sogin ML, Relman DA: The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. *PLoS Biol* 2008, **6**:e280. 210.137/journal.pbio.0060280.
6. Cotter P, Stanton C, Ross R, Hill C: The impact of antibiotics on the gut microbiota as revealed by high throughput DNA sequencing. *Discov Med* 2012, **13**:193–199.
7. Sommer MOA, Dantas G, Church GM: Functional characterization of the antibiotic resistance reservoir in the human microflora. *Sci* 2009, **325**:1128–1131.
8. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM: Aminoglycosides: activity and resistance. *Antimicrob Agents Chemother* 1999, **43**:727–737.
9. Page MGP: Beta-Lactam Antibiotics. *Antibiot Discov Dev* 2012, **1**:79–117.
10. Tipper DJ, Strominger JL: Mechanism of action of penicillins: a proposal based on their structural similarity to acyl-D-alanyl-D-alanine. *Proc Natl Acad Sci U S A* 1965, **54**:1133–1141.
11. Bush K: Characterization of beta-lactamases. *Antimicrob Agents Chemother* 1989, **33**:259–263.
12. Bush K: Alarming beta-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. *Curr Opin Microbiol* 2010, **13**:558–564.
13. Kotra LP, Mobashery S: β -Lactam antibiotics, β -lactamases and bacterial resistance. *Bull Inst Pasteur* 1998, **96**:139–150.
14. Tipper D: Mode of action of β -lactam antibiotics. *Rev Infect Dis* 1979, **1**:39–53.
15. Hughes VM, Datta N: Conjugative plasmids in bacteria of the 'pre-antibiotic' era. *Nature* 1983, **302**:725–726.
16. Bhullar K, Waglchner N, Pawlowski A, Koteva K, Banks ED, Johnston MD, Barton HA, Wright GD: Antibiotic resistance is prevalent in an isolated cave microbiome. *PLoS ONE* 2012, **7**:e34953.
17. D'Costa VM, King CE, Kalan L, Morar M, Sung WWL, Schwarz C, Froese D, Zazula G, Calmels F, Debruyne R: Antibiotic resistance is ancient. *Nature* 2011, **477**:457–461.
18. Dallenne C, Da Costa A, Decré D, Favier C, Arlet G: Development of a set of multiplex PCR assays for the detection of genes encoding important β -lactamases in Enterobacteriaceae. *J Antimicrob Chemother* 2010, **65**:490–495.
19. Vannuffel P, Gigi J, Ezzedine H, Vandercam B, Delmee M, Wauters G, Gala J-L: Specific detection of methicillin-resistant Staphylococcus species by multiplex PCR. *J Clin Microbiol* 1995, **33**:2864–2867.
20. Heuer H, Krögerrecklenfort E, Wellington E, Egan S, Elsas J, Overbeek L, Collard JM, Guillaume G, Karagouni A, Nikolakopoulou T: Gentamicin resistance genes in environmental bacteria: prevalence and transfer. *FEMS Immunol Med Microbiol* 2002, **42**:289–302.
21. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA: Diversity of the human intestinal microbial flora. *Science* 2005, **308**:1635–1638.
22. Bailey JK, Pinyon JL, Anantham S, Hall RM: Distribution of the blaTEM gene and blaTEM-containing transposons in commensal Escherichia coli. *J Antimicrob Chemother* 2011, **66**:745–751.
23. Tenover FC, Huang MB, Rasheed JK, Persing DH: Development of PCR assays to detect ampicillin resistance genes in cerebrospinal fluid samples containing Haemophilus influenzae. *Eur J Clin Microbiol* 1994, **32**:2729–2737.

24. Briñas L, Zarazaga M, Sáenz Y, Ruiz-Larrea F, Torres C: β -Lactamases in ampicillin-resistant *Escherichia coli* isolates from foods, humans, and healthy animals. *Antimicrob Agents Chemother* 2002, **46**:3156–3163.
25. Monstein H-J, Tärnberg M, Nilsson LE: Molecular identification of CTX-M and blaOXY/K1 β -lactamase genes in Enterobacteriaceae by sequencing of universal M13-sequence tagged PCR-amplicons. *BMC Infect Dis* 2009, **9**:7–15.
26. De Fátima Silva Lopes M, Ribeiro T, Abrantes M, Figueiredo Marques JJ, Tenreiro R, Crespo MTB: Antimicrobial resistance profiles of dairy and clinical isolates and type strains of enterococci. *Int J Food Microbiol* 2005, **103**:191–198.
27. Schmitz F-J, Fluit AC, Gondolf M, Beyrau R, Lindenlauf E, Verhoef J, Heinz H-P, Jones ME: The prevalence of aminoglycoside resistance and corresponding resistance genes in clinical isolates of staphylococci from 19 European hospitals. *J Antimicrob Chemother* 1999, **43**:253–259.
28. Matsumura M, Katakura Y, Imanaka T, Aiba S: Enzymatic and nucleotide sequence studies of a kanamycin-inactivating enzyme encoded by a plasmid from thermophilic bacilli in comparison with that encoded by plasmid pUB110. *J bacteriol* 1984, **160**:413–420.
29. Ubukata K, Yamashita N, Gotoh A, Konno M: Purification and characterization of aminoglycoside-modifying enzymes from *Staphylococcus aureus* and *Staphylococcus epidermidis*. *Antimicrob Agents Chemother* 1984, **25**:754–759.
30. Hegstad K, Mikalsen T, Coque T, Werner G, Sundsfjord A: Mobile genetic elements and their contribution to the emergence of antimicrobial resistant *Enterococcus faecalis* and *Enterococcus faecium*. *Clin Microbiol Infect* 2010, **16**:541–554.
31. Ferretti JJ, Gilmore K, Courvalin P: Nucleotide sequence analysis of the gene specifying the bifunctional 6'-aminoglycoside acetyltransferase 2'-aminoglycoside phosphotransferase enzyme in *Streptococcus faecalis* and identification and cloning of gene regions specifying the two activities. *J bacteriol* 1986, **167**:631–638.
32. Fouhy F, Ross RP, Fitzgerald GF, Stanton C, Cotter PD: PCR sequencing data of aminoglycoside and beta-lactam resistance genes. *BMC microbiology* 2013. <http://dx.doi.org/10.6070/H42V2D1V>; 2013.
33. Morris D, Whelan M, Corbett-Feeney G, Cormican M, Hawkey P, Li X, Doran G: First Report of Extended-Spectrum- β -Lactamase-Producing *Salmonella enterica* Isolates in Ireland. *Antimicrob Agents Chemother* 2006, **50**:1608–1609.
34. Perilli M, Felici A, Franceschini N, De Santis A, Pagani L, Luzzaro F, Oratore A, Rossolini GM, Knox JR, Amicosante G: Characterization of a new TEM-derived beta-lactamase produced in a *Serratia marcescens* strain. *Antimicrob Agents Chemother* 1997, **41**:2374–2382.
35. Zhao W-H, Hu Z-Q, Chen G, Matsushita K, Fukuchi K, Shimamura T: Characterization of imipenem-resistant *Serratia marcescens* producing IMP-type and TEM-type beta-lactamases encoded on a single plasmid. *Microbiol Res* 2007, **162**:46–52.
36. Morosini MI, Canton R, Martinez-Beltran J, Negri MC, Perez-Diaz JC, Baquero F, Blazquez J: New extended-spectrum TEM-type beta-lactamase from *Salmonella enterica* subsp. *enterica* isolated in a nosocomial outbreak. *Antimicrob Agents Chemother* 1995, **39**:458–461.
37. Wong MHY, Liu M, Wan HY, Chen S: Characterization of Extended-Spectrum- β -Lactamase-Producing *Vibrio parahaemolyticus*. *Antimicrob Agents Chemother* 2012, **56**:4026–4028.
38. Mokracka J, Koczura R, Kaznowski A: Multiresistant Enterobacteriaceae with class 1 and class 2 integrons in a municipal wastewater treatment plant. *Water Res* 2012, **46**:3353–3363.
39. Coque TM, Oliver A, Pérez-Díaz JC, Baquero F, Cantón R: Genes Encoding TEM-4, SHV-2, and CTX-M-10 Extended-Spectrum β -Lactamases Are Carried by Multiple *Klebsiella pneumoniae* Clones in a Single Hospital (Madrid, 1989 to 2000). *Antimicrob Agents Chemother* 2002, **46**:500–510.
40. Paterson DL, Hujer KM, Hujer AM, Yeiser B, Bonomo MD, Rice LB, Bonomo RA: Extended-spectrum β -lactamases in *Klebsiella pneumoniae* bloodstream isolates from seven countries: dominance and widespread prevalence of SHV-and CTX-M-type β -lactamases. *Antimicrob Agents Chemother* 2003, **47**:3554–3560.
41. Heritage J, M'Zali FH, Gascoyne-Binzi D, Hawkey PM: Evolution and spread of SHV extended-spectrum β -lactamases in Gram-negative bacteria. *Journal of antimicrobial chemotherapy* 1999, **44**:309–318.
42. Babini GS, Livermore DM: Antimicrobial resistance amongst *Klebsiella* spp. collected from intensive care units in Southern and Western Europe in 1997–1998. *J Antimicrob Chemother* 2000, **45**:183–189.
43. Pitout J, Sanders C, Sanders W Jr: Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli. *Am J Med* 1997, **103**:51–59.
44. Bonnet R: Growing group of extended-spectrum β -lactamases: the CTX-M enzymes. *Antimicrob Agents Chemother* 2004, **48**:1–14.
45. Pitout JDD, Laupland KB: Extended-spectrum [beta]-lactamase-producing Enterobacteriaceae: an emerging public-health concern. *Lancet Infect Dis* 2008, **8**:159–166.
46. Coque T, Baquero F, Canton R: Increasing prevalence of ESB β -producing Enterobacteriaceae in Europe. *Euro Surveillance* 2008, **13**:19–29.
47. CDC: Antibiotic resistance threats in the United States. 2013. Retrieved from www.cdc.gov/drugresistance/threat-report-2013/.
48. Boyd DA, Tyler S, Christianson S, McGeer A, Muller MP, Willey BM, Bryce E, Gardam M, Nordmann P, Mulvey MR: Complete nucleotide sequence of a 92-kilobase plasmid harboring the CTX-M-15 extended-spectrum beta-lactamase involved in an outbreak in long-term-care facilities in Toronto, Canada. *Antimicrob Agents Chemother* 2004, **48**:3758–3764.
49. Lavollay M, Mamlouk K, Frank T, Akpabie A, Burghoffer B, Redjeb SB, Bercion R, Gautier V, Arlet G: Clonal dissemination of a CTX-M-15 β -lactamase-producing *Escherichia coli* strain in the Paris area, Tunis, and Bangui. *Antimicrob Agents Chemother* 2006, **50**:2433–2438.
50. Cho YJ, Moon DC, Jin JS, Choi CH, Lee YC, Lee JC: Genetic basis of resistance to aminoglycosides in *Acinetobacter* spp. and spread of armA in *Acinetobacter baumannii* sequence group 1 in Korean hospitals. *Diagn Microbiol Infect Dis* 2009, **64**:185–190.
51. Lambert T, Gerbaud G, Courvalin P: Characterization of the chromosomal aac (6)-Ij gene of *Acinetobacter* sp. 13 and the aac (6)-Ih plasmid gene of *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 1994, **38**:1883–1889.
52. Shaw K, Cramer C, Rizzo M, Mierzwa R, Gewain K, Miller G, Hare R: Isolation, characterization, and DNA sequence analysis of an AAC (6)-II gene from *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 1989, **33**:2052–2062.
53. Park CH, Robicsek A, Jacoby GA, Sahn D, Hooper DC: Prevalence in the United States of aac (6)-Ib-cr encoding a ciprofloxacin-modifying enzyme. *Antimicrob Agents Chemother* 2006, **50**:3953–3955.
54. Dijkshoorn L, Nemeč A, Seifert H: An increasing threat in hospitals: multidrug-resistant *Acinetobacter baumannii*. *Nat Rev Microbiol* 2007, **5**:939–951.
55. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA: Global challenge of multidrug-resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2007, **51**:3471–3484.
56. Vakulenko SB, Donabedian SM, Voskresenskiy AM, Zervos MJ, Lerner SA, Chow JW: Multiplex PCR for detection of aminoglycoside resistance genes in enterococci. *Antimicrob Agents Chemother* 2003, **47**:1423–1426.
57. Vanhoof R, Godard C, Content J, Nyssen H, Hannecart-Pokorni E: Detection by polymerase chain reaction of genes encoding aminoglycoside-modifying enzymes in methicillin-resistant *Staphylococcus aureus* isolates of epidemic phage types. *J Med Microbiol* 1994, **41**:282–290.
58. Han D, Unno T, Jang J, Lim K, Lee S-N, Ko G, Sadowsky MJ, Hur H-G: The occurrence of virulence traits among high-level aminoglycosides resistant *Enterococcus* isolates obtained from feces of humans, animals, and birds in South Korea. *Int J Food Microbiol* 2011, **144**:387–392.
59. Montecalvo MA, Horowitz H, Gedris C, Carbonaro C, Tenover FC, Issah A, Cook P, Wormser GP: Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant *Enterococcus faecium* bacteremia in an adult oncology unit. *Antimicrob Agents Chemother* 1994, **38**:1363–1367.
60. Leclercq R: Enterococci acquire new kinds of resistance. *Clin Infect Dis* 1997, **24**:S80–S84.
61. McKay G, Thompson P, Wright G: Broad spectrum aminoglycoside phosphotransferase type III from *Enterococcus*: overexpression, purification, and substrate specificity. *Biochemistry* 1994, **33**:6936–6944.
62. Shaw K, Rather P, Hare R, Miller G: Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. *Microbiol Rev* 1993, **57**:138–163.

63. Fouhy F, Guinane CM, Hussey S, Wall R, Ryan CA, Dempsey EM, Murphy B, Ross RP, Fitzgerald GF, Stanton C: **High-throughput sequencing reveals the incomplete, short-term, recovery of the infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamycin.** *Antimicrob Agents Chemother* 2012, **56**:5811–5820.
64. de Vries LE, Vallès Y, Agersø Y, Vaishampayan PA, García-Montaner A, Kuehl JV, Christensen H, Barlow M, Francino MP: **The gut as reservoir of antibiotic resistance: microbial diversity of tetracycline resistance in mother and infant.** *PLoS ONE* 2011, **6**:e21644.

doi:10.1186/1471-2180-14-25

Cite this article as: Fouhy *et al.*: A degenerate PCR-based strategy as a means of identifying homologues of aminoglycoside and β -lactam resistance genes in the gut microbiota. *BMC Microbiology* 2014 **14**:25.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

